fundmomentum.vc

Nina Capital (III)

Spain
Pre Seed
Share

About Nina Capital (III)

Nina Capital (III) is a venture capital firm based in Spain, focusing on Pre-Seed stage investments. The fund actively supports founders building innovative solutions in Digital Health, providing strategic guidance and capital to help startups scale.

Investment Focus

Location / RegionSpain
Funding StagePre Seed
Industry Focus
Digital Health

Investor Signals Profile

active

Sweet Spot

Clinical outcomes + workflow moat; real problems; regulatory compounding

clinical AI
proprietary clinical data
regulatory moats
workflow embedded AI
pharma decision tools
real clinical outcomes vs AI hype

Bullish Signals

Active hiring in US portfolioexternal
11,703 LinkedIn followerslinkedin
Portfolio bet on clinical AI simulationlinkedin
Backing pre-trial pharma decision toolslinkedin
Digital patient simulation before trialslinkedin
Targets trial design + indication strategylinkedin
Backs tools avoiding expensive trial dead endslinkedin
Portfolio targets pharma portfolio decisions earlylinkedin
Focuses on clinical workflow + regulatory compoundingexternal
Identifies proprietary data as moat vs lab infrastructureexternal
Marta Zanchi: frontier labs shift AI vulnerability landscapelinkedin
Explicitly contrarian on wet lab infrastructure durabilitylinkedin
Consensus forming around proprietary data + workflow moatslinkedin
Nina reposting: health tech solving real clinical problems undervaluedlinkedin
87.5% VC dollars chasing AI megadeals; clinical founders competeexternal
Capital inefficiency: genuine clinical outcomes overlooked vs AI labelsexternal

Contrarian Signals

Novel therapy prediction still unprovenlinkedin
Wet lab infrastructure trade becoming crowdedexternal
Automated foundries commoditizing lab capacityexternal
Lab moat less durable than investor consensuslinkedin
Remote experimentation eroding physical lab barrierslinkedin
AI Series D+: 6.6x valuations; non-AI: 1.6xexternal
2021-22 startups trading 54-59% discount without AI labelexternal

Founder Do's

Build proprietary clinical data advantages
Own workflow position in development pipeline
Embed in messy human-mediated processes
Target regulatory + market access layers
Compound clearances over time
Focus on real clinical outcomes; not AI label

Founder Don'ts

Standalone AI tools without proprietary data
Bet on wet lab infrastructure as moat
Rely on scientific reasoning alone
Lead with 'AI company' positioning; prove clinical impact

Key GPs & Partners

MZ
Marta G. Zanchi
Partner
biotech AI strategistsystems thinkercontrarian
KS
Kyle Sherrill
Partner
biotechoperationsexecution
SA
Sebastian Anastassiou
Partner
scientificbiotechfrontier reasoning

Unlock Investor Signals

$29/month for full signal access. Cancel anytime.

View PlansBrowse all Signal Profiles →

Fund Overview

Fund Size€50M
Saves0
Website
LinkedIn

Key People

Marta Zanchi

Marta G. ZanchiPartner
Kyle SherrillPartner
Sebastian AnastassiouPartner

Related Funds

Samaipata Fund III

€110M
Spain
Seed
Ai Ml, Saas, Ecommerce
Fund Manager:José del Barrio, Eduardo Díez-Hochleitner
Seed
Ai Ml
Saas
Ecommerce

Miura Fund IV

€475M
Spain
Late Stage
Enterprise Software
Fund Manager:Luis Seguí, Carlos Julià
Late Stage
Enterprise Software

Acurio Ventures III

€150M
Spain
Pre Seed
Ecommerce
Fund Manager:Ander Michelena, Jon Uriarte, Bart Tompkins
Pre Seed
Ecommerce